Adaptive Biotechnologies (ADPT) Free Cash Flow (2018 - 2026)

Adaptive Biotechnologies has disclosed Free Cash Flow across 9 years of filings, most recently posting -$10.3 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$10.3 million, up 63.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$30.6 million (up 65.29% YoY), and the FY2025 annual result was -$48.9 million, up 50.5% from the prior year.
• Free Cash Flow came in at -$10.3 million for Q1 2026 at Adaptive Biotechnologies, down from -$236000.0 in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$236000.0 in Q4 2025 to a low of -$67.5 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$28.5 million (2023), against an average of -$29.5 million.
• Across the five-year window, Free Cash Flow tumbled 204.81% in 2022 and jumped 98.12% in 2025, its largest moves.
• Adaptive Biotechnologies' Free Cash Flow stood at -$29.1 million in 2022, then increased by 9.64% to -$26.3 million in 2023, then surged by 52.22% to -$12.6 million in 2024, then surged by 98.12% to -$236000.0 in 2025, then sank by 4278.39% to -$10.3 million in 2026.
• The last three Free Cash Flow figures came in at -$10.3 million (Q1 2026), -$236000.0 (Q4 2025), and -$7.6 million (Q3 2025), per Business Quant data.